ZVRA vs. GTHX, PBYI, QURE, MACK, EBS, ACIU, RENB, ATOS, CDT, and OVID
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include G1 Therapeutics (GTHX), Puma Biotechnology (PBYI), uniQure (QURE), Merrimack Pharmaceuticals (MACK), Emergent BioSolutions (EBS), AC Immune (ACIU), Renovaro (RENB), Atossa Therapeutics (ATOS), Conduit Pharmaceuticals (CDT), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:ZVRA) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Zevra Therapeutics has higher earnings, but lower revenue than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 8.2% of G1 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Zevra Therapeutics presently has a consensus price target of $19.50, indicating a potential upside of 304.56%. G1 Therapeutics has a consensus price target of $8.67, indicating a potential upside of 81.69%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than G1 Therapeutics.
In the previous week, Zevra Therapeutics had 3 more articles in the media than G1 Therapeutics. MarketBeat recorded 18 mentions for Zevra Therapeutics and 15 mentions for G1 Therapeutics. Zevra Therapeutics' average media sentiment score of 0.69 beat G1 Therapeutics' score of 0.61 indicating that Zevra Therapeutics is being referred to more favorably in the media.
G1 Therapeutics has a net margin of -36.40% compared to Zevra Therapeutics' net margin of -181.76%. G1 Therapeutics' return on equity of -74.75% beat Zevra Therapeutics' return on equity.
Zevra Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
G1 Therapeutics received 293 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 65.81% of users gave G1 Therapeutics an outperform vote.
Summary
Zevra Therapeutics beats G1 Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
